Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.86

-2.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (7761)	1/17/2003 3:25:52 PM
From: Biomaven	of 52153

From a letter in this weeks NEJM from the French doctors involved: We interpret these findings as the consequence of the insertional mutagenesis event, a risk that is potentially associated with retrovirally mediated gene transfer and that has previously been considered to be very low in humans.4 For this reason, a thorough reassessment of the potential risk of retrovirally mediated gene therapy is warranted. It is likely that additional factors may have contributed to the adverse event in our patient, including a varicella?zoster virus infection five months before clinically detectable lymphoproliferation, which may have stimulated immune reactivity of the / T-cell clone, or a selective growth advantage conferred by c expression in the transduced cells. Genetic predisposing factors for childhood cancer are also possible, since medulloblastomas have developed in the proband's sister and a first-degree relative. So this might just have been bad luck. Given that these particular patients die pretty quickly without this procedure, I suspect they will resume treatments using retroviruses for this disorder. But clearly this is a warning flag for retrovirus use for other, less fatal, diseases. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next